Cystic Fibrosis Combination Drug Gets FDA Nod

The FDA approved a cystic fibrosis treatment that combines Vertex’s Kalydeco with the new drug tezacaftor. The combined product will be sold as Symdeko.

The approval was based on clinical trials of two proposed triple combinations involving Kalydeco that showed improvements in lung function in subjects.

The new treatment is the first in a planned series of combination products that could treat up to 90 percent of cystic fibrosis patients.